Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Yange Tian

12PUBLICATIONS
12CO-AUTHORS
Biomechanical engineeringMechanobiologyTraditional Chinese medicine and treatmentsNgā rongoā me ngā whakamaimoa o te Māori (Māori medicine and treatments)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

Sort by Publication Date:
|Jul 01, 2026
Effective-Component Compatibility of Bufei Yishen Formula Alleviates Alveolar Epithelial Barrier Damage in COPD Through Inhibition of p38 MAPK Phosphorylation.

|Mar 23, 2026
Effective Component Compatibility of Bufei Yishen Formula III Alleviates Pulmonary Vascular Inflammation in COPD: Via VEGF<sub>165</sub>/P38 MAPK Pathway.

Qinghua Song, Lili Cui, Ruilong Lu

|Jul 10, 2025
Effective-Component Compatibility of Bufei Yishen Formula III Protects Lung Air-Blood Barrier by Regulating the Oxidative Stress: via the Nuclear Factor-E<sub>2</sub>-Related Factor 2 Pathway.

Kexin Xu, Xuejie Shao, Ruilong Lu

|Jan 29, 2025
The Effective Compound Combination of Bufei Yishen Formula III Improves the Mitochondrial Dysfunction via Inhibiting JNK/Sab Pathway in COPD Mice.

Mengwei Song, Mi Han, Haoyu Zhang

|Aug 10, 2024
Impact of different processing methods of Ligustrum lucidum Ait. on kidney-yin deficiency: a study based on pharmacodynamics and metabolomics research.

Shu-Ding Sun, Di Zhao, Xue-Fang Liu

|Jan 09, 2023
Effective Component Compatibility of Bufei Yishen Formula III Which Regulates the Mucus Hypersecretion of COPD Rats via the miR-146a-5p/EGFR/MEK/ERK Pathway.

Jindi Ma, Xuefang Liu, Yumeng Wei

Pageof 2

Frequent Collaborators

4 joint publications

Jiansheng Li

3 joint publications

Jiansheng Li

2 joint publications

Suxiang Feng

2 joint publications

Ya Li

2 joint publications

Xuefang Liu

1 joint publications

Di Zhao

1 joint publications

Suyun Li

1 joint publications

Brian G Oliver

1 joint publications

Fanli Jin

1 joint publications

Jindi Ma

Frequent Collaborators

4 joint publications

Jiansheng Li

3 joint publications

Jiansheng Li

2 joint publications

Suxiang Feng

2 joint publications

Ya Li